New combo aims to tackle tough myeloma cases

NCT ID NCT07454382

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing whether adding cyclophosphamide to elranatamab helps people with relapsed or refractory multiple myeloma who have risk factors that make standard treatment less effective. About 26 participants will receive the combination therapy. The main goal is to see how many achieve a complete response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elranatamab (a bispecific antibody) and cyclophosphamide (a chemotherapy drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with multiple myeloma that has not responded well to other therapies.
What could go wrong: This is a small, early-phase trial (26 participants) with no control group, so results may not apply broadly. Side effects from the drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.